After this morning's 13.1% surge to $268.61 per share, Alnylam Pharmaceuticals might just keep moving past its target price of $270.06. With an average analyst rating of buy, and target prices from $160.5 to $400.0, the stock's next move is anyone's guess.
Alnylam Pharmaceuticals's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.1%. The stock's short ratio is 2.31. The company's insiders own 0.42% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 92.1%. In conclusion, we believe there is mixed market sentiment regarding Alnylam Pharmaceuticals.
Institutions Invested in Alnylam Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Capital World Investors | 10% | 12,789,236 | $3,435,316,494 |
| 2024-03-31 | Vanguard Group Inc | 9% | 11,994,261 | $3,221,778,271 |
| 2024-03-31 | FMR, LLC | 8% | 9,967,996 | $2,677,503,259 |
| 2024-03-31 | Blackrock Inc. | 7% | 9,025,007 | $2,424,206,998 |
| 2024-03-31 | Wellington Management Group, LLP | 6% | 7,209,005 | $1,936,410,727 |
| 2024-06-30 | Baillie Gifford and Company | 5% | 6,032,656 | $1,620,431,639 |
| 2024-03-31 | Dodge & Cox Inc | 3% | 3,811,480 | $1,023,801,586 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 3% | 3,685,753 | $990,030,059 |
| 2024-03-31 | Capital International Investors | 3% | 3,651,217 | $980,753,344 |
| 2024-03-31 | State Street Corporation | 3% | 3,191,373 | $857,234,654 |
